Jingchuan Zhang

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Matthew R. Janes, Jingchuan Zhang, Lian‐Sheng Li et al. · Cell · 2018 · 1.2K citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +12

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Barry R. Davies, Hannah E. Greenwood, Phillippa Dudley et al. · Molecular Cancer Therapeutics · 2012 · 461 citations · Full text

Medicine, Oncology, Pharmacology +16

<i>FGFR2</i> Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547

Liang Xie, Xinying Su, Lin Zhang et al. · Clinical Cancer Research · 2013 · 241 citations

Medicine, Oncology, Pharmacology +16

Translating the Therapeutic Potential of AZD4547 in <i>FGFR1</i> -Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models

Jingchuan Zhang, Lin Zhang, Xinying Su et al. · Clinical Cancer Research · 2012 · 155 citations

Medicine, Oncology, Pharmacology +17

Two‐chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5

Jingchuan Zhang, Kevin P. Claffey, Ramasamy Sakthivel et al. · The FASEB Journal · 2000 · 112 citations

Life Sciences, Cell Biology, Pharmacology +14